ADVERSE COURSE OF VITILIGO: MANAGEMENT TACTICS OF PATIENTS FROM RISK GROUPS
Introduction. Vitiligo is one of the most common hypomelanoses, in which the destruction of functioning melanocytes causes depigmentation of the skin, hair and mucous membranes. The genes encrypting brain-derived neurotropic factor (BDNF) and corticotropin-releasing hormone (CRH) might be the conceivable contributors to the development of vitiligo.
Objective. This study was aimed at investigation of the association between psychoemotional disorders, neurotransmitters and their gene polymorphism with the area of depigmentation in patients with vitiligo in order to identify risk groups for the progressive course of the disease and develop an algorithm.
Materials and methods. The study included 93 patients with vitiligo. The area of depigmentation was calculated using the Vitiligo Extent Score (VES) online program. The psychological status of the participants was assessed using the PHQ-SADS scale. Serum levels of BDNF and CRH were measured by enzyme-linked immunosorbent assay (ELISA) technique. Genotyping for the rs11030094 polymorphism of the BDNF gene and rs242924 of the corticotropin-releasing hormone receptor 1 (CRH-R1) gene was performed by real-time polymerase chain reaction (PCR).
Results. Our investigation showed that the T allele and the TT genotype of the CRH-R1 rs242924 gene polymorphism at 3-4 times increase the risk of a progressive course of the vitiligo, while the G allele and the GT genotype, on the contrary, indicate its resistance. In addition, patients with mild and moderate anxiety were in 1.6 times more likely to progress the disease.
Conclusion. Thus, the T allele and TT genotype of the CRH-R1 rs242924 gene polymorphism mediated by anxiety may be factors in the progressive course of vitiligo. The results of the study of the psychological status and neurogenetic features of the presented sample made it possible to develop an algorithm for managing patients with a progressive course of vitiligo.
Assiya A. Kussainova1, https://orcid.org/0000-0002-5738-0804
Laura T. Kassym2*, https://orcid.org/0000-0003-4448-6455
Almira K. Akhmetova1, https://orcid.org/0000-0002-8938-3401
Zaituna A. Khismetova1, https://orcid.org/0000-0001-5937-3045
Tatyana M. Belyaeva1, https://orcid.org/0000-0002-2565-2393
1 NJSC "Semey Medical University", Semey city, Republic of Kazakhstan;
2 NJSC "Astana Medical University", Astana city, Republic of Kazakhstan.
1. Варжапетян А.А., Дороженок И.Ю., Ломоносов К.М. Витилиго и коморбидные психосоматические расстройства // Российский журнал кожных и венерических болезней. 2019. Т. 22. С. 1-2.
2. Рахимов У.С., Мухамадиева К.М., Исматуллоева С.С. Нейровегетативные нарушения в патогенезе витилиго // Вестник Авиценны. 2017. Т. 19. №. 4. С. 550-555.
3. Тальникова Е.Е., Свенская Ю.И., Добдина А.Ю., Утц С.Р. Витилиго: современные методы терапии // Саратовский научно-медицинский журнал. 2017. 13(3) С. 668-673.
4. Усовецкий И.А. Поэтапное лечение различных форм витилиго: автореф. дис. на соиск. учен. степ. д-ра мед. наук. Москва. 2012. 44 с.
5. Balci D.D., Yonden Z., Yenin J.Z., Okumus N. Serum homocysteine, folic acid and vitamin B12 levels in vitiligo. // Eur J Dermatol. 2009 Jul-Aug;19(4):382-3. doi: 10.1684/ejd.2009.0671. Epub 2009 May 18. PMID: 19451048.
6. Ezzedine K., Lim H.W., Suzuki T., Katayama I., Hamzavi I., Lan C.C., Goh B.K., Anbar T., Silva de Castro C., Lee A.Y., Parsad D., van Geel N., Le Poole I.C., Oiso N., Benzekri L., Spritz R., Gauthier Y., Hann S.K., Picardo M., Taieb A. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference // Pigment Cell Melanoma Res. 2012 May.25(3):E1-13. doi: 10.1111/j.1755-148X.2012.00997.x. PMID: 22417114; PMCID: PMC3511780.
7. Giri P.S., Begum R., Dwivedi M. Meta-analysis for association of TNFA-308(G > A) SNP with vitiligo susceptibility // Gene. 2022 Jan 30;809:146027. doi: 10.1016/j.gene.2021.146027. Epub 2021 Oct 18. PMID: 34673212.
8. Halder R.M., Chappell J.L. Vitiligo update // Semin Cutan Med Surg. 2009 Jun;28(2):86-92. doi: 10.1016/j.sder.2009.04.008. PMID: 19608058.
9. Henning S.W., Jaishankar D., Barse L.W., Dellacecca E.R., Lancki N., Webb K., Janusek L., Mathews H.L., Price R.N. Jr., Le Poole I.C. The relationship between stress and vitiligo: Evaluating perceived stress and electronic medical record data // PLoS One. 2020 Jan 27;15(1):e0227909. doi: 10.1371/journal.pone.0227909. PMID: 31986193; PMCID: PMC6984686.
10. Krüger C., Schallreuter K.U. A review of the worldwide prevalence of vitiligo in children/adolescents and adults // International journal of dermatology. 2012. Т.51. №.10. С. 1206-1212.
11. Kussainova A., Kassym L., Akhmetova A., Dvoryankova E., Glushkova N., Khismetova Z., Adilgozhina S., Tuleutayeva R., Kaskabayeva A., Massabayeva M., Pak L., Semenova Y. Associations between serum levels of brain-derived neurotrophic factor, corticotropin releasing hormone and mental distress in vitiligo patients // Sci Rep. 2022 May 4;12(1):7260. doi: 10.1038/s41598-022-11028-8. PMID: 35508633; PMCID: PMC9068776.
12. Kussainova A., Kassym L., Bekenova N., Akhmetova A., Glushkova N., Kussainov A., Semenova Y. Gene polymorphisms and serum levels of BDNF and CRH in vitiligo patients // PloS one, 2022. 17(7), e0271719.
13. Manolache L., Benea V. Stress in patients with alopecia areata and vitiligo // J Eur Acad Dermatol Venereol. 2007 Aug;21(7):921-8. doi: 10.1111/j.1468-3083.2006.02106.x. PMID: 17659001.
14. Mastore M., Kohler L., Nappi A.J. Production and utilization of hydrogen peroxide associated with melanogenesis and tyrosinase-mediated oxidations of DOPA and dopamine // FEBS J. 2005 May;272(10):2407-15. doi: 10.1111/j.1742-4658.2005.04661.x. PMID: 15885091.
15. Papadopoulos L., Bor R., Legg C., Hawk J.L. Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology // Clin Exp Dermatol. 1998 Nov;23(6):243-8. doi: 10.1046/j.1365-2230.1998.00384.x. PMID: 10233617.
16. Rodrigue-Gervais I.G., Saleh M. Genetics of inflammasome-associated disorders: a lesson in the guiding principals of inflammasome function // Eur J Immunol. 2010 Mar;40(3):643-8. doi: 10.1002/eji.200940225. PMID: 20201021.
17. Rodrigues M., Ezzedine K., Hamzavi I., Pandya A.G., Harris J.E. Vitiligo Working Group. New discoveries in the pathogenesis and classification of vitiligo // J Am Acad Dermatol. 2017 Jul;77(1):1-13. doi: 10.1016/j.jaad.2016.10.048. PMID: 28619550.
18. Salem R.M., Abdelrahman A.M.N., Abd El‐Kareem H.M., Seif M. DEFB1 gene polymorphisms modify vitiligo extent and response to NB‐UVB phototherapy // Dermatologic Therapy. 2021. 34(3). e14921. DOI:10.1111/dth.14921
19. Shaker O.G., Eltahlawi S.M., Tawfic S.O., Eltawdy A.M., Bedair N.I. Corticotropin-releasing hormone (CRH) and CRH receptor 1 gene expression in vitiligo // Clin Exp Dermatol. 2016 Oct;41(7):734-40. doi: 10.1111/ced.12907. PMID: 27663146.
20. Shaker O.G., El-Tahlawi S.M. Is there a relationship between homocysteine and vitiligo? A pilot study // Br J Dermatol. 2008 Sep;159(3):720-4. doi: 10.1111/j.1365-2133.2008.08712.x. Epub 2008 Jul 4. PMID: 18616781.
21. Silpa-Archa N., Pruksaeakanan C., Angkoolpakdeekul N., Chaiyabutr C., Kulthanan K., Ratta-Apha W., Wongpraparut C. Relationship Between Depression and Quality of Life Among Vitiligo Patients: A Self-assessment Questionnaire-based Study // Clin Cosmet Investig Dermatol. 2020 Aug 4;13:511-520. doi: 10.2147/CCID.S265349. PMID: 32801827; PMCID: PMC7414931.
22. Silverberg J.I., Silverberg N.B. Serum homocysteine as a biomarker of vitiligo vulgaris severity: a pilot study // J Am Acad Dermatol. 2011 Feb;64(2):445-7. doi: 10.1016/j.jaad.2010.08.025. PMID: 21238838.
23. Silverberg J.I., Silverberg N.B. Vitiligo disease triggers: psychological stressors preceding the onset of disease // Cutis. 2015 May;95(5):255-62. PMID: 26057504.
24. Zhang Y., Cai Y., Shi M., Jiang S., Cui S., Wu Y., Gao X.H., Chen H.D. The Prevalence of Vitiligo: A Meta-Analysis. // PLoS One. 2016 Sep 27;11(9):e0163806. doi: 10.1371/journal.pone.0163806. PMID: 27673680; PMCID: PMC5038943
25. Zhang H.Z., Wu J.H., Huang Q., Yang Q., Sima Q., Chen K.Y., Li Z.R., He G.H. Associations of methylenetetrahydrofolate reductase gene (MTHFR) rs1801131 and rs1801133 polymorphisms with susceptibility to vitiligo: A meta-analysis // J Cosmet Dermatol. 2021 Jul;20(7):2359-2368. doi: 10.1111/jocd.13857. Epub 2020 Dec 3. PMID: 33219596.
References:
1. Varzhapetyan A.A., Dorozhenok I.Yu., Lomonosov K.M. Vitiligo i komorbidnye psikhosomaticheskie rasstroistva [Vitiligo and comorbid psychosomatic disorders]. Rossiiskii zhurnal kozhnykh i venericheskikh boleznei [Russian journal of skin and venereal diseases]. 2019. T. 22. pp. 1-2. [in Russian]
2. Rakhimov U.S., Mukhamadieva K.M., Ismatulloeva S.S. Neirovegetativnye narusheniya v patogeneze vitiligo [Neurovegetative disorders in the pathogenesis of vitiligo]. // Vestnik Avitsenny [Herald of Avicenna]. 2017. T. 19. №. 4. pp. 550-555. [in Russian]
3. Tal'nikova E.E., Svenskaya Yu.I., Dobdina A.Yu., Utts S.R. Vitiligo: sovremennye metody terapii [Vitiligo: modern methods of therapy]. // Saratovskii nauchno-meditsinskii zhurnal [Saratov Scientific Medical Journal]. 2017. 13(3), pp. 668-673. [in Russian]
4. Usovetskii I.A. Poetapnoe lechenie razlichnykh form vitiligo: avtoref. dis. na soisk. uchen. step. d-ra med. Nauk [ Staged treatment of various forms of vitiligo: dissertation abstract for the degree of doctor of medical sciences]. Moskva. 2012. 44 p.
Number of Views: 92
Category of articles:
Original articles
Bibliography link
Kussainova A.A., Kassym L.T., Akhmetova A.K., Khismetova. Z.A., Belyaeva T.M. Adverse course of vitiligo: management tactics of patients from risk groups // Nauka i Zdravookhranenie [Science & Healthcare]. 2022, (Vol.24) 5, pp. 68-76. doi 10.34689/SH.2022.24.5.009Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS